Navigation Links
ImaginAb, Inc. Announces Formation of Singapore Subsidiary, ImaginAb Molecular Imaging Pte Ltd.
Date:9/6/2011

LOS ANGELES and SINGAPORE, Sept. 6, 2011 /PRNewswire/ -- ImaginAb, Inc. is pleased to announce the establishment of a wholly owned Singapore-based subsidiary, ImaginAb Molecular Imaging Pte Ltd (IMI). IMI is the first step in the company's international expansion and marks a significant increase in research capability for the organization. IMI will be established to provide GLP pre-clinical molecular imaging services to both the US parent company and select biopharma partnerships, including optical imaging and positron emission tomography (PET) services.

Christian P. Behrenbruch, Ph.D, ImaginAb's CEO, commented, "Singapore has tremendous resources and facilities of interest to ImaginAb. We already have a close dialog with several A*Star Research Institutes (RIs) and a formalized collaboration with Sir David Lane's lab at the Institute of Molecular Biology (IMB)." The establishment of IMI will strengthen the possibility of further collaborations with A*Star, university labs and several global pharmaceutical companies who have established translational medicine units in Singapore.

"Establishing a significant research footprint in Singapore has been a straightforward process, greatly facilitated by the ease of working with A*Star, EDB and other government stakeholders who are committed to bringing highly innovative US companies to a growing and dynamic biotech cluster," commented Dr. Behrenbruch. "We are impressed with the quality of industry-accessible core resources and the international talent base in Singapore. We also expect ImaginAb's footprint in Singapore will also enable the company to better service a rapidly growing client base in Korea, Japan and China."

About ImaginAb, Inc.

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Anna Wu
http://www.profnetconnect.com/anna_wu


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ImaginAb, Inc. Concludes Licensing Agreement With UCLA for Novel Radiochemistry Technology
2. ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research
3. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
4. Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update
5. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
6. Genprex Announces New Branding
7. BioMed Realty Announces Repurchase at Option of Holders and Redemption of 4.50% Exchangeable Senior Notes Due 2026
8. BioInformatics LLC Announces the Life Science Industry Awards on November 15, 2011 in Washington, DC
9. Jeunesse Global Announces New Medical Advisory Board Member and Admittance Into the Direct Selling Association (DSA).
10. BD Biosciences Announces Winners of Research Grant Program
11. SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for any ... So which eye do you rinse first if a dangerous substance enters both eyes? It’s ... Wash with its unique dual eye piece. , “Whether its dirt and debris, or ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):